• Biomarker identifies men with prostate cancer who may benefit from chemotherapy

    11 monthes ago - By Healio

    A validated assay for detecting nuclear-localized androgen receptor splice variant 7 protein in circulating tumor cells identified men with prostate cancer who lived longer with taxane chemotherapy than with an androgen receptor signaling inhibitor, according to results of a multi-institutional cohort study.
    “The test should be considered for patients for whom increased OS is an objective,” Howard I. Scher, MD, co-chair of the Center for Mechanism Based Therapy and head of the Biomarker Development Initiative at Memorial Sloan Kettering Cancer Center, and colleagues wrote. “For
    Read more ...